Click here for an updated version of this article.
NEW YORK, Oct. 19 (GenomeWeb News) - Shares in DeCode Genetics this afternoon slipped to $6.97 from their high of $7.70, reached this morning after the company announced positive results from an ongoing drug trial.
Shares in the Icelandic pharmacogenomics company closed at $6.61 on the Nasdaq yesterday.
As GenomeWeb News reported, DeCode licensed the drug, which is in early-stage Phase IIa testing, from Bayer last November.
Results of the study showed the drug, called DG031, to have significantly reduced levels of two chemical biomarkers associated with arterial inflammation and myocardial infarction risk.